MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas.

The apparent diffusion coefficient (ADC) determined from MR diffusion tensor imaging (DTI) has shown promise for distinguishing World Health Organization grade II astrocytoma (AS) from the more prognostically favorable grade II oligodendroglioma (OD). Since mixed oligoastrocytomas (OAs) with codeletions in chromosomes 1p and 19q confer prognoses similar to those of OD, we questioned whether a previously determined ADC-based criterion for distinguishing OD and AS would hold on an independent set of gliomas that included OA with codeleted or intact 1p/19q chromosomes. We also questioned whether the ADC is associated with the tumor microstructure. ADC colormaps generated from presurgical DTI scans were used to guide the collection of biopsies from each tumor. The median normalized ADC distinguished OD from AS with 91% sensitivity and 92% specificity. 1p/19q codeleted OAs were always classified as ODs, while 1p/19q intact OAs were always classified as ASs. There were positive associations between the ADC and both the SMI-31 score of axonal disruption and the fraction of tumor cells in the biopsies. The ADC of OD and 1p/19q codeleted OA was more associated with tumor fraction, while the ADC of AS and 1p/19q intact OA was more associated with SMI-31 score. We conclude that our previously determined threshold median ADC can distinguish grade II OD and AS on a new patient cohort and that the distinctions extend to OA with codeleted and intact 1p/19q chromosomes. Further, the ADC in grade II gliomas is associated with the fraction of tumor cells and degree of axonal disruption in tumor subregions.

[1]  M. J. van den Bent New perspectives for the diagnosis and treatment of oligodendroglioma , 2001, Expert review of anticancer therapy.

[2]  Inas S. Khayal,et al.  Apparent diffusion coefficient and fractional anisotropy of newly diagnosed grade II gliomas , 2009, NMR in biomedicine.

[3]  Usha Sinha,et al.  Relationships Between Choline Magnetic Resonance Spectroscopy, Apparent Diffusion Coefficient and Quantitative Histopathology in Human Glioma , 2000, Journal of Neuro-Oncology.

[4]  K. Swanson,et al.  Correlation of in vitro infiltration with glioma histological type in organotypic brain slices , 2004, British Journal of Cancer.

[5]  Rebecca A Betensky,et al.  Imaging Correlates of Molecular Signatures in Oligodendrogliomas , 2004, Clinical Cancer Research.

[6]  P. Basser,et al.  Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. , 1996, Journal of magnetic resonance. Series B.

[7]  D B Vigneron,et al.  Registration of images from sequential MR studies of the brain , 1994, Journal of magnetic resonance imaging : JMRI.

[8]  M. Berger,et al.  Coregistration Accuracy and Detection of Brain Shift Using Intraoperative Sononavigation during Resection of Hemispheric Tumors , 2003, Neurosurgery.

[9]  N. Probst-Hensch,et al.  Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas , 2004, Acta Neuropathologica.

[10]  A. von Deimling,et al.  Molecular pathology of oligodendroglial tumors. , 2009, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[11]  K. Kono,et al.  The role of diffusion-weighted imaging in patients with brain tumors. , 2001, AJNR. American journal of neuroradiology.

[12]  J. Cairncross,et al.  PCV for Oligodendroglial Tumors: In Search of Prognostic Factors for Response and Survival , 2001, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[13]  L. Deangelis,et al.  Long-term outcome of low-grade oligodendroglioma and mixed glioma , 2000, Neurology.

[14]  Stephen M. Smith,et al.  Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm , 2001, IEEE Transactions on Medical Imaging.

[15]  David W. Smith,et al.  The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. , 1992, Journal of neurosurgery.

[16]  D. Bihan,et al.  Differentiation of benign versus pathologic compression fractures with diffusion-weighted MR imaging: a closer step toward the "holy grail" of tissue characterization? , 1998 .

[17]  R. Jenkins,et al.  Genetic alterations and chemotherapeutic response in human diffuse gliomas , 2001, Expert review of anticancer therapy.

[18]  D. Le Bihan Differentiation of benign versus pathologic compression fractures with diffusion-weighted MR imaging: a closer step toward the "holy grail" of tissue characterization? , 1998, Radiology.

[19]  M. Bent New perspectives for the diagnosis and treatment of oligodendroglioma. , 2001 .

[20]  Inas S. Khayal,et al.  Characterization of low‐grade gliomas using RGB color maps derived from ADC histograms , 2009, Journal of magnetic resonance imaging : JMRI.

[21]  Toshinori Hirai,et al.  Usefulness of diffusion‐weighted MRI with echo‐planar technique in the evaluation of cellularity in gliomas , 1999, Journal of magnetic resonance imaging : JMRI.

[22]  D. Louis,et al.  Molecular Genetic Evidence for Subtypes of Oligoastrocytomas , 1997, Journal of neuropathology and experimental neurology.

[23]  B. Scheithauer,et al.  Oligodendrogliomas: the Mayo Clinic experience. , 1992, Journal of neurosurgery.

[24]  J. Buckner,et al.  Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Vigneron,et al.  An automated technique for the quantitative assessment of 3D‐MRSI data from patients with glioma , 2001, Journal of magnetic resonance imaging : JMRI.

[26]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[27]  G. Krol,et al.  Low-grade oligodendroglioma responds to chemotherapy , 1996, Neurology.

[28]  Hiroyuki Aburatani,et al.  Selective Expression of a Subset of Neuronal Genes in Oligodendroglioma with Chromosome 1p Loss , 2004, Brain pathology.

[29]  D. Louis WHO classification of tumours of the central nervous system , 2007 .

[30]  Rebecca A Betensky,et al.  Histopathological‐Molecular Genetic Correlations in Referral Pathologist‐Diagnosed Low‐Grade “Oligodendroglioma” , 2002, Journal of neuropathology and experimental neurology.

[31]  Paul S Tofts,et al.  Apparent diffusion coefficient histograms may predict low‐grade glioma subtype , 2007, NMR in biomedicine.

[32]  Carol Walker,et al.  Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. , 2006, Brain : a journal of neurology.